Tarsus Pharmaceuticals
TARS
73.01
-4.66
-6.00%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.01
-4.66
-6.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 5.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 108.11% -5.42pp
- Institutions
- 323 +3
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund61.11%
Hedge Fund23.71%
VC/PE Fund9.83%
Public Company8.99%
Private Company2.89%
Individual/Insider2.75%
Government Pension Fund0.74%
Endowment Fund0.48%
Insurance Company0.33%
Top holders as of 2026-09-30
BlackRock
7.84% · 3.87M sh
Deep Track Capital, LP
7.44% · 3.67M sh
RTW Investments, LP
6.81% · 3.36M sh
FMR
6.64% · 3.27M sh
Janus Henderson Group plc
5.70% · 2.81M sh
Paradigm Biocapital Advisors LP
5.63% · 2.78M sh
Vanguard Capital Management, LLC
3.81% · 1.88M sh
Morgan Stanley
3.47% · 1.71M sh
Tang Capital Management, LLC
3.57% · 1.57M sh
Morgan Stanley Investment Management Inc.
3.47% · 1.71M sh
Jennison Associates LLC
3.37% · 1.66M sh
Millennium Management LLC
3.25% · 1.43M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Bobak Azamian | Chairperson & CEO | 1.75% |
| William Link | Independent Director | 0.19% |
| Seshadri Neervannan | Chief Operating Officer | 0.16% |
| Bryan Wahl | General Counsel | 0.13% |
| Aziz Mottiwala | Former Chief Commercial Officer | 0.12% |
| Jeffrey S. Farrow | CFO & Chief Strategy Officer | 0.12% |
| Dianne Whitfield | Chief Human Resources Officer | 0.07% |
| Andrew Goldberg | Independent Director | 0.04% |
| Wendy Yarno | Lead Independent Director | 0.03% |
| Elizabeth Yeu-Lin | Chief Medical Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | Neera Clase | Chief Commercial Officer | Other Derivative Acquisition | +6,678 | -- |
| 2026-11-02 | Neera Clase | Chief Commercial Officer | Other Derivative Acquisition | +10,587 | $72.64 |
| 2026-10-31 | Neera Clase | Chief Commercial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-14 | William Link | Independent Director | Automatic Disposition | -12,299 | $78.33–80.01 |
| 2026-09-14 | William Link | Independent Director | Derivative Exercise and Sale | -201 | $78.33 |
| 2026-09-14 | David E. Pyott | Independent Director | Derivative Exercise and Retained | +201 | -- |
| 2026-09-14 | Wendy Yarno | Lead Independent Director | Derivative Exercise and Retained | +302 | -- |
| 2026-09-03 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $90.27–91.27 |
| 2026-09-03 | Seshadri Neervannan | Chief Operating Officer | Open Market Disposition | -4,564 | $85.00 |
| 2026-09-03 | Elizabeth Yeu-Lin | Chief Medical Officer | Automatic Disposition | -13,953 | $85.00–90.00 |
| 2026-09-01 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $80.06 |
| 2026-09-01 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -8,000 | $81.80 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Officer | Automatic Disposition | -11,578 | $73.86–80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -5,387 | $80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -1,590 | $80.00 |
| 2026-08-31 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -77,698 | $73.96 |
| 2026-08-31 | Elizabeth Yeu-Lin | Chief Medical Officer | Intent to Sell (Form 144) | -4,601 | $73.86 |
| 2026-08-24 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -81,332 | $71.85 |
| 2026-08-18 | Aziz Mottiwala | Former Chief Commercial Officer | Intent to Sell (Form 144) | -53,043 | $72.00 |
| 2026-06-24 | William Link | Independent Director | Other Derivative Acquisition | +3,223 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
Tarsus Pharmaceuticals discussion 0 comments